135 related articles for article (PubMed ID: 10732718)
1. Interleukin 2 gene therapy of surgical minimal residual tumour disease: characterization of cytolytic effector cells from tumour progressors and regressors.
Hájková R; Indrová M; Jandlová T; Bubeník J; Reinis M
Folia Biol (Praha); 1999; 45(6):227-31. PubMed ID: 10732718
[TBL] [Abstract][Full Text] [Related]
2. Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases.
Porgador A; Tzehoval E; Vadai E; Feldman M; Eisenbach L
Cancer Res; 1995 Nov; 55(21):4941-9. PubMed ID: 7585534
[TBL] [Abstract][Full Text] [Related]
3. Early-appearing tumour-infiltrating natural killer cells play a crucial role in the generation of anti-tumour T lymphocytes.
Kurosawa S; Harada M; Matsuzaki G; Shinomiya Y; Terao H; Kobayashi N; Nomoto K
Immunology; 1995 Jun; 85(2):338-46. PubMed ID: 7642226
[TBL] [Abstract][Full Text] [Related]
4. Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2.
Rosenstein M; Yron I; Kaufmann Y; Rosenberg SA
Cancer Res; 1984 May; 44(5):1946-53. PubMed ID: 6608989
[TBL] [Abstract][Full Text] [Related]
5. Age-related decrease in transplantability of human tumours in nu/nu mice.
Bubeník J; Kieler J; Jandlová T; Símova J
Anticancer Res; 1992; 12(5):1695-8. PubMed ID: 1444237
[TBL] [Abstract][Full Text] [Related]
6. IL-2 gene transfer in immunotherapy of cancer: local administration of IL-2-activated lymphocytes and X63-m-IL-2 cells constitutively producing IL-2 inhibits growth of plasmacytomas in syngeneic mice.
Bubeník J; Lotzová E; Indrová M; Simová J; Jandlová T; Savary CA
Nat Immun Cell Growth Regul; 1991; 10(5):247-55. PubMed ID: 1758466
[TBL] [Abstract][Full Text] [Related]
7. Growth inhibition of Candida albicans hyphae by CD8+ lymphocytes.
Beno DW; Stöver AG; Mathews HL
J Immunol; 1995 May; 154(10):5273-81. PubMed ID: 7730631
[TBL] [Abstract][Full Text] [Related]
8. Leukocyte Interleukin, Inj. (LI) augmentation of natural killer cells and cytolytic T-lymphocytes.
Chirigos MA; Talor E; Sidwell RW; Burger RA; Warren RP
Immunopharmacol Immunotoxicol; 1995 May; 17(2):247-64. PubMed ID: 7650289
[TBL] [Abstract][Full Text] [Related]
9. Local IL-4 delivery enhances immune reactivity to murine tumors: gene therapy in combination with IL-2.
Pippin BA; Rosenstein M; Jacob WF; Chiang Y; Lotze MT
Cancer Gene Ther; 1994 Mar; 1(1):35-42. PubMed ID: 7621236
[TBL] [Abstract][Full Text] [Related]
10. Increase in sensitivity of the microcytotoxicity assay by T cell growth factor (IL-2)-containing preparations.
Indrová M; Bubeník J
Folia Biol (Praha); 1984; 30(1):43-9. PubMed ID: 6609090
[TBL] [Abstract][Full Text] [Related]
11. Activation and phenotyping of LAK generated by exposure to product of cells transformed by interleukin 2 cDNA.
Bubeník J; Zeuthen J; Símová J; Jandlová T; Bubeníková D; Radzikowski C
Anticancer Res; 1992; 12(3):965-7. PubMed ID: 1622155
[TBL] [Abstract][Full Text] [Related]
12. Detection and characterization of anti-tumour effector cells in Meth-A-bearing mice treated with recombinant human interleukin 2.
Naruo KI; Hinuma S; Shiho O; Houkan T; Ootsu K; Tsukamoto K
Clin Exp Immunol; 1989 May; 76(2):278-83. PubMed ID: 2788049
[TBL] [Abstract][Full Text] [Related]
13. [Natural killer activity of splenocytes of C3HA mice in the early period after transplantation of hepatoma 22a cells].
Filatova NA; Malygin AM; Pleskach VA; Fel' VIa
Eksp Onkol; 1987; 9(6):52-5. PubMed ID: 3436291
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy of murine sarcomas with interleukin 2. II. Activation of killer cells by human recombinant IL-2.
Indrová M; Bubeník J; Toulcová A
Folia Biol (Praha); 1986; 32(6):392-8. PubMed ID: 3492397
[TBL] [Abstract][Full Text] [Related]
15. Lysis of fresh natural killer-resistant tumor cells by lectin-activated syngeneic and allogeneic murine splenocytes.
Mazumder A; Rosenstein M; Rosenberg SA
Cancer Res; 1983 Dec; 43(12 Pt 1):5729-34. PubMed ID: 6640524
[TBL] [Abstract][Full Text] [Related]
16. [Characteristics of production and sorption of interleukin 2 by lymphoid cells during growth of transplanted sarcoma].
Kushko LIa; Semenova-Kobzar' RA; Iudin VM; Koval'chuk EV; Berezhnaia NM
Eksp Onkol; 1988; 10(1):34-7. PubMed ID: 3259499
[TBL] [Abstract][Full Text] [Related]
17. Chrysotile A affects YAC-1 cytolytic activity of spleen cells.
Moniewska A; Szyba K; Jaźwiec B; Lange A
Arch Immunol Ther Exp (Warsz); 1989; 37(1-2):61-8. PubMed ID: 2559675
[TBL] [Abstract][Full Text] [Related]
18. [The effect of antitumor vaccine on the recurrence of solid tumors in mice subjected to surgery].
Zatula DG; Bikhunov VL; Zagoruĭko EE
Eksp Onkol; 1984; 6(1):47-9. PubMed ID: 6499731
[TBL] [Abstract][Full Text] [Related]
19. [Tumor vaccination in renal cell carcinoma with and without interleukin-2 (IL-2) as adjuvant. A clinical contribution to the development of effective active specific immunization].
Pomer S; Thiele R; Staehler G; Drehmer I; Löhrke H; Schirrmacher V
Urologe A; 1995 May; 34(3):215-20. PubMed ID: 7610516
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-2 and syngeneic bone marrow transplantation in a murine fibrosarcoma model.
Ho SP; Stebler B; Ershler WB
Lymphokine Cytokine Res; 1991 Apr; 10(1-2):101-4. PubMed ID: 1873353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
